{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:00:45Z","timestamp":1790413245324,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The risk of coccidioidomycosis (CM) as a life-threatening respiratory illness or disseminated CM (DCM) increases as much as 150-fold in immunosuppressed patients. The safety of biologic response modifiers (BRMs) as treatment for patients with autoimmune disease (AI) in CM-endemic regions is not well defined. We sought to determine that risk in the Tucson and Phoenix areas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study reviewing demographics, Arizona residency length, clinical presentations, specific AI diagnoses, CM test results, and BRM treatments in electronic medical records of patients \u226518 years old with International Classification of Diseases (ICD-10) codes for CM and AI from 1 October 2017 to 31 December 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We reviewed 944 charts with overlapping ICD-10 codes for CM and AI, of which 138 were confirmed to have both diagnoses. Male sex was associated with more CM (P\u00a0=\u00a0.003), and patients with African ancestry were 3 times more likely than those with European ancestry to develop DCM (P\u00a0&amp;lt;\u00a0.001). Comparing CM+\/AI+ (n = 138) with CM+\/AI\u2013 (n = 449) patients, there were no significant differences in CM clinical presentations. Patients receiving BRMs had 2.4 times more DCM compared to pulmonary CM (PCM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>AI does not increase the risk of any specific CM clinical presentation, and BRM treatment of most AI patients does not lead to severe CM. However, BRMs significantly increase the risk of DCM, and prospective studies are needed to identify the immunogenetic subset that permits BRM-associated DCM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac032","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T22:00:06Z","timestamp":1643320806000},"source":"Crossref","is-referenced-by-count":11,"title":["Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity"],"prefix":"10.1093","volume":"9","author":[{"given":"Fariba M","family":"Donovan","sequence":"first","affiliation":[{"name":"Valley Fever Center for Excellence, University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"},{"name":"University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferris A","family":"Ramadan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Arizona College of Public Health, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Lim","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E","family":"Buchfuhrer","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebia N","family":"Khan","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine\u2013Phoenix, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie P","family":"DeQuillfeldt","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M","family":"Davis","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Kaveti","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"De Shadarevian","sequence":"additional","affiliation":[{"name":"A. T. Still University School of Osteopathic Medicine, Mesa, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Bedrick","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Arizona College of Public Health, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N","family":"Galgiani","sequence":"additional","affiliation":[{"name":"Valley Fever Center for Excellence, University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"},{"name":"University of Arizona College of Medicine\u2013Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"2022021116031430500_CIT0001","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/mmy\/myy095","article-title":"Update on the epidemiology of coccidioidomycosis in the United States.","volume":"57","author":"McCotter","year":"2019","journal-title":"Med Mycol"},{"key":"2022021116031430500_CIT0002","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/mmy\/myy037","article-title":"coccidioidomycosis in Latin America.","volume":"57","author":"Laniado-Laborin","year":"2019","journal-title":"Med Mycol"},{"key":"2022021116031430500_CIT0003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00003246-199801000-00017","article-title":"Septic shock in coccidioidomycosis.","volume":"26","author":"Arsura","year":"1998","journal-title":"Crit Care Med"},{"key":"2022021116031430500_CIT0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3201\/eid2302.160505","article-title":"Risk factors for disseminated coccidioidomycosis, United States.","volume":"23","author":"Odio","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2022021116031430500_CIT0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/archinte.1982.00340160069017","article-title":"Coccidioidomycosis in renal replacement therapy.","volume":"142","author":"Cohen","year":"1982","journal-title":"Arch Intern Med"},{"key":"2022021116031430500_CIT0006","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/acr.21784","article-title":"Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.","volume":"64","author":"Taroumian","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022021116031430500_CIT0007","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016","article-title":"Biologic agents and tuberculosis.","volume":"4","author":"Dobler","year":"2016","journal-title":"Microbiol Spectr"},{"key":"2022021116031430500_CIT0008","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2020.02.009","article-title":"Hepatitis B virus reactivation potentiated by biologics.","volume":"34","author":"Ogawa","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2022021116031430500_CIT0009","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/mmy\/myy019","article-title":"Coccidioidomycosis in selected immunosuppressed hosts.","volume":"57","author":"Blair","year":"2019","journal-title":"Med Mycol"},{"key":"2022021116031430500_CIT0010","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis.","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022021116031430500_CIT0011","first-page":"1","article-title":"Approach to management of coccidioidomycosis in patients receiving inhibitors of tumor necrosis factor-\u03b1.","volume":"25","author":"Blair","year":"2016","journal-title":"Infect Dis Clin Pract"},{"key":"2022021116031430500_CIT0012","volume-title":"Cerner Corporation: International Directory of Company Histories,","author":"Cerner.","year":"1997"},{"key":"2022021116031430500_CIT0013","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2022021116031430500_CIT0014","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomedical Inform"},{"key":"2022021116031430500_CIT0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.3.3.247","article-title":"Serology of coccidioidomycosis.","volume":"3","author":"Pappagianis","year":"1990","journal-title":"Clin Microbiol Rev"},{"key":"2022021116031430500_CIT0016","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","article-title":"Statistical notes for clinical researchers: chi-squared test and Fisher\u2019s exact test.","volume":"42","author":"Kim","year":"2017","journal-title":"Restor Dent Endod"},{"key":"2022021116031430500_CIT0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of 2 random variables is stochastically larger than the other.","volume":"18","author":"Mann","year":"1947","journal-title":"Ann Math Stat"},{"key":"2022021116031430500_CIT0018","volume-title":"R: a language and environment for statistical computing","author":"Team RC.","year":"2020"},{"key":"2022021116031430500_CIT0019","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3201\/eid1611.100475","article-title":"Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007-2008.","volume":"16","author":"Tsang","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"2022021116031430500_CIT0020","first-page":"185","article-title":"Coccidioidomycosis: epidemiology.","volume":"5","author":"Brown","year":"2013","journal-title":"Clin Epidemiol"},{"key":"2022021116031430500_CIT0021","first-page":"105","article-title":"Increase in coccidioidomycosis\u2014California, 2000-2007.","volume":"58","author":"Centers for Disease Control and Prevention.","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022021116031430500_CIT0022","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1128\/iai.32.2.897-907.1981","article-title":"Human sex hormones stimulate the growth and maturation of Coccidioides immitis.","volume":"32","author":"Drutz","year":"1981","journal-title":"Infect Immun"},{"key":"2022021116031430500_CIT0023","first-page":"e8094","article-title":"The prevalence of autoimmune disorders in women: a narrative review.","volume":"12","author":"Angum","year":"2020","journal-title":"Cureus"},{"key":"2022021116031430500_CIT0024","volume-title":"QuickFacts Arizona","author":"United States Census Bureau.","year":"2020"},{"key":"2022021116031430500_CIT0025","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1086\/319203","article-title":"Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995\u20131996.","volume":"32","author":"Rosenstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2022021116031430500_CIT0026","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4065\/mcp.2010.0423","article-title":"Coccidioidomycosis in African Americans.","volume":"86","author":"Ruddy","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2022021116031430500_CIT0027","article-title":"Impact of disseminated coccidioidomycosis in Arizona, 2007-2008.","author":"Foley"},{"key":"2022021116031430500_CIT0028","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/infdis\/165.4.710","article-title":"In vitro assessment of cellular immunity in human coccidioidomycosis: relationship between dermal hypersensitivity, lymphocyte transformation, and lymphokine production by peripheral blood mononuclear cells from healthy adults.","volume":"165","author":"Ampel","year":"1992","journal-title":"J Infect Dis"},{"key":"2022021116031430500_CIT0029","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/civ388","article-title":"The return of delayed-type hypersensitivity skin testing for coccidioidomycosis.","volume":"61","author":"Wack","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022021116031430500_CIT0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/B:MYCO.0000003580.93839.71","article-title":"Measurement of cellular immunity in human coccidioidomycosis.","volume":"156","author":"Ampel","year":"2003","journal-title":"Mycopathologia"},{"key":"2022021116031430500_CIT0031","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11046-012-9555-6","article-title":"A reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis.","volume":"174","author":"Johnson","year":"2012","journal-title":"Mycopathologia"},{"key":"2022021116031430500_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.aje.a119404","article-title":"Serological tests in the diagnosis and prognosis of coccidioidomycosis.","volume":"52","author":"Smith","year":"1950","journal-title":"Am J Epidemiol"},{"key":"2022021116031430500_CIT0033","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/mmy\/myaa109","article-title":"Coccidioidomycosis in patients with various inflammatory disorders treated with tumor necrosis factor alpha inhibitors.","volume":"59","author":"Delafield","year":"2021","journal-title":"Med Mycol"},{"key":"2022021116031430500_CIT0034","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/ofid\/ofaa417.041","article-title":"Common population variants cause susceptibility to disseminated coccidioidomycosis.","volume":"7","author":"Hsu","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2022021116031430500_CIT0035","doi-asserted-by":"crossref","first-page":"e1587","DOI":"10.1093\/cid\/ciaa739","article-title":"Clinician practice patterns that result in the diagnosis of coccidioidomycosis before or during hospitalization.","volume":"73","author":"Pu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022021116031430500_CIT0036","article-title":"Use of disease-modifying antirheumatic drugs, biologic response modifiers and corticosteroids, and subsequent risk of coccidioidomycosis infection among Medicare beneficiaries.","volume-title":"Arthritis Rheumatol","author":"Sudano","year":"2017"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac032\/42308743\/ofac032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/3\/ofac032\/42499084\/ofac032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/3\/ofac032\/42499084\/ofac032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T16:03:52Z","timestamp":1644595432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac032\/6516076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac032","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2022,1,27]]},"article-number":"ofac032"}}